Investor Insights

This summary was created by AI, based on 2 opinions in the last 12 months.

Cullinan Oncology, Inc. (CGEM-Q) has received mixed reviews from experts. While one expert recommends covering the position due to a net investment loss of 27%, another expert reiterates it as a top pick, emphasizing the company's focus on oncology therapies, growing pipeline, strong financials, and potential upside. The stock's performance seems to be a matter of debate among experts.

Consensus
Mixed
Valuation
Undervalued
premium

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK
(A Top Pick Jun 06/23, Down 30.8%)Stockchase Research Editor: Michael O’Reilly

Our PAST TOP PICK with CGEM has triggered its stop at $8.50.  To remain disciplined, we recommend covering the position at this time. This will result in a net investment loss of 27%, when combined with previous recommendations. 

biotechnology / pharmaceutical
premium

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK
Stockchase Research Editor: Michael O'Reilly

We reiterate this biopharma company focused on oncology therapies, as a TOP PICK.   Pilot projects are continuing to advance and they have a growing pipeline of new prospects.  It trades under book value, supporting a 14% ROE.  Cash reserves are growing, while debt is retired.   We recommend maintaining the stop at $8.50, looking to achieve $17.00 -- upside of 36%.  Yield 0%  

(Analysts’ price target is $29.00)
biotechnology / pharmaceutical
premium

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK
Stockchase Research Editor: Michael O’Reilly

CGEM is a unique pharmaceutical company that collaborates with other developers and academia to develop drugs to help cancer patients.  It has six on-going products in its pipeline.  It trades below book value, at 6x earnings, and supports a 19% ROE.  We like that it is low beta compared to the market.  We recommend a stop-loss at $8.50, looking to achieve $17 — upside potential of 50%.  Yield 0%

(Analysts’ price target is $28.75)
biotechnology / pharmaceutical
Showing 1 to 3 of 3 entries
  • «
  • 1
  • »

Cullinan Oncology, Inc.(CGEM-Q) Rating

Ranking : 4 out of 5

Bullish - Buy Signals / Votes : 1

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 1

Stockchase rating for Cullinan Oncology, Inc. is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Cullinan Oncology, Inc.(CGEM-Q) Frequently Asked Questions

What is Cullinan Oncology, Inc. stock symbol?

Cullinan Oncology, Inc. is a American stock, trading under the symbol CGEM-Q on the NASDAQ (CGEM). It is usually referred to as NASDAQ:CGEM or CGEM-Q

Is Cullinan Oncology, Inc. a buy or a sell?

In the last year, 1 stock analyst published opinions about CGEM-Q. 1 analyst recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Cullinan Oncology, Inc..

Is Cullinan Oncology, Inc. a good investment or a top pick?

Cullinan Oncology, Inc. was recommended as a Top Pick by on . Read the latest stock experts ratings for Cullinan Oncology, Inc..

Why is Cullinan Oncology, Inc. stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Cullinan Oncology, Inc. worth watching?

In the last year, there was no coverage of Cullinan Oncology, Inc. published on Stockchase.

What is Cullinan Oncology, Inc. stock price?

On 2024-03-28, Cullinan Oncology, Inc. (CGEM-Q) stock closed at a price of $17.04.